APPLICATION OF MONOCLONAL ANTIBODY FOR THE NEW TREATMENT AND DIAGNOSIS OF DIGESTIVE CANCER.

单克隆抗体在消化道癌新治疗和诊断中的应用。

• 批准号: 07457277
• 负责人: TAKAHASHI Toshio
• 金额: $ 4.61万
• 依托单位: KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07457277/
• 关键词: DIGESTIVE CANCER; MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY; MICRO-FERRITE; 外科手術; 画像診断; 化学療法; 磁性鉄; 転移; 神経温存; イメージング

Huma/mouse chmeric antibody had been developed and anti-cancer drug neocarzinostatin could be bound with Fab fragment of chiemric antibody without loosing both anticancer and antibody activites. Clinical phase 1 study had been carried out and no seriouse adverse effects had been observed up to 40,000 units of immunoconojugates. The production of human anti-mouse antibody (HAMA) had been strongly suppressed in patients receiving chimeric antibody compared with patients receiving mouse immunocojugates.Fine ferromagnetics had been successfully conojugated with antibody. The stability and capacity of the cojugates to bind with target cancer cell had been well preserved. The imaging of tumor tissue in experimental animal suggested its usefullness in MRI imaging in vivo. This new ferromagnetic immunoconjugate could be applied for ferro-immuno-guided surgery in the near future.

人/鼠嵌合抗体已研制成功，抗癌药物新制癌素可与嵌合抗体Fab段结合而不丧失抗癌活性和抗体活性。已经进行了临床I期研究，在高达40，000单位的免疫缀合物中没有观察到严重的不良反应。与接受小鼠免疫缀合物的患者相比，接受嵌合抗体的患者中人抗小鼠抗体（HAMA）的产生被强烈抑制。偶联物的稳定性和与靶癌细胞结合的能力得到了很好的保留。实验动物肿瘤组织的成像结果表明，该方法可用于活体MRI成像。这种新的铁磁免疫偶联物可以在不久的将来应用于铁免疫引导手术。

项目成果

C.Sakakura: "Overexpression of Bax Sensitizes Breast Cancer MCF-7 Cells to Cisplatin and Etoposide" Surgery Today. 27. 676-679 (1997)

C.Sakakura：“Bax 的过度表达使乳腺癌 MCF-7 细胞对顺铂和依托泊苷敏感”，今日手术。

C.Sakakura: "Increased Apoptosis Rate by Hyperthermochemo radiotheraphy for Advanced Rectal Cancers" Surgery Today. 27. 773-776 (1997)

C.Sakakura：“通过热化疗放疗提高晚期直肠癌的细胞凋亡率”《今日手术》。

E.Otsuji, T.Yamaguchi, H.Tsuruta, Y.Yata, H.Nishi, K.Okamoto, K.Taniguchi, M.Kato, T.Kotani, K.Kitamura, T.Takahashi: "Applicability of monoclonal antibody fab fragments as a carrier of neocarzinostatin in targeting chemotherapy" J.Surg.Oncol.61. 149-154

E.Otsuji、T.Yamaguchi、H.Tsuruta、Y.Yata、H.Nishi、K.Okamoto、K.Taniguchi、M.Kato、T.Kotani、K.Kitamura、T.Takahashi：“单克隆抗体工厂的适用性

E.Otsuji, T.Yamaguchi, H.Tsuruta, Y.Yata, H.Nishi, K.Okamoto, K.Taniguchi, M.Kato, T.Kotani, K.Kitamura, T.Takahashi: "Effects of neocarzinostain-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts" Brit.J.Cancer. 73. 1178-1182

E.Otsuji、T.Yamaguchi、H.Tsuruta、Y.Yata、H.Nishi、K.Okamoto、K.Taniguchi、M.Kato、T.Kotani、K.Kitamura、T.Takahashi：“新癌菌染色剂嵌合的效果

T.Yamaguchi, T.Takahashi, K.Kitamura, E.Otsuji, T.Kotani, M.Kato, Y.Yata, K.Okamoto, H.Nishi, D.Ichikawa, K.Yamamoto: "Diagnosis and targeting therapy of colon cancer with antibody" Gan-to-Kagakuryohou. 23. 549-553 (1996)

T.Yamaguchi、T.Takahashi、K.Kitamura、E.Otsuji、T.Kotani、M.Kato、Y.Yata、K.Okamoto、H.Nishi、D.Ichikawa、K.Yamamoto：“诊断和靶向治疗